published meta-analysis   sensitivity analysis   studies

baricitinib in COVID 19 all comers - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsRECOVERY, 2022 0.87 [0.77; 0.98] 0.87[0.77; 0.98]RECOVERY, 202210%8,156NAnot evaluable deathsdetailed resultsRECOVERY, 2022 0.87 [0.77; 0.98] 0.87[0.77; 0.98]RECOVERY, 202210%8,156NAnot evaluable death or ventilationdetailed resultsRECOVERY, 2022 0.90 [0.81; 0.99] 0.90[0.81; 0.99]RECOVERY, 202210%7,905NAnot evaluable mechanical ventilationdetailed resultsRECOVERY, 2022 0.87 [0.74; 1.02] 0.87[0.74; 1.02]RECOVERY, 202210%7,905NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-04-18 23:17 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 94 - treatments: 727 - roots T: 290